These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34856624)

  • 1. Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients.
    Gao L; Huang H; Zhang L; Zhang N; Fu Y; Zhu D; Bi Y; Feng W
    Exp Clin Endocrinol Diabetes; 2022 Jun; 130(6):358-367. PubMed ID: 34856624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study.
    Chen K; Chen L; Shan Z; Wang G; Qu S; Qin G; Yu X; Xin W; Hsieh TH; Mu Y
    Diabetes Obes Metab; 2024 Feb; 26(2):690-698. PubMed ID: 37945546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial.
    Wen Q; Fang S; Liang Y; Tian Y; Chen Y; Yuan J; Chen Q
    Front Endocrinol (Lausanne); 2023; 14():1156521. PubMed ID: 37347114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies in patients with type 2 diabetes: a randomized clinical trial.
    Han CY; Lu JP; Ye XM; Jin HY; Xu WW; Wang P; Zhang M
    Front Endocrinol (Lausanne); 2023; 14():1267503. PubMed ID: 38125788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model.
    Fang X; Du Z; Duan C; Zhan S; Wang T; Zhu M; Shi J; Meng J; Zhang X; Yang M; Zuo Y
    Life Sci; 2021 Apr; 270():118966. PubMed ID: 33482185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial.
    Cai H; Chen Q; Duan Y; Zhao Y; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1106868. PubMed ID: 36777344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity.
    Wang G; Wu P; Qiu Y; Dong X; Wang Y; Chi Y; Zhang F; Li Y; Zhang J; Huang Z; Du X; Du Z
    Arch Endocrinol Metab; 2021 Nov; 65(4):421-427. PubMed ID: 34283904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review.
    Lentferink YE; Knibbe CAJ; van der Vorst MMJ
    Drugs; 2018 Dec; 78(18):1887-1901. PubMed ID: 30511324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of metformin for weight management in patients without type 2 diabetes.
    Desilets AR; Dhakal-Karki S; Dunican KC
    Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial.
    Liu X; Yang W; Liu J; Huang X; Fang Y; Ming J; Lai J; Fu J; Ji Q; Wang L
    J Diabetes; 2023 Oct; 16(2):. PubMed ID: 37864379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients.
    Firouzjaei A; Li GC; Wang N; Liu WX; Zhu BM
    Nutr Diabetes; 2016 May; 6(5):e209. PubMed ID: 27136447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.
    Su N; Li Y; Xu T; Li L; Kwong JS; Du H; Ren K; Li Q; Li J; Sun X; Li S; Tian H
    Int J Cardiol; 2016 Sep; 219():293-300. PubMed ID: 27343423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice.
    Al-Barazanji K; McNulty J; Binz J; Generaux C; Benson W; Young A; Chen L
    J Pharmacol Exp Ther; 2015 Jun; 353(3):496-504. PubMed ID: 25770135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
    Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
    Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N
    J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Multiphase Modified Ketogenic Diet: An Effective and Safe Tool for Weight Loss in Chinese Obese Patients.
    Wu W; Zhou Q; Yuan P; Qiao D; Deng S; Cheng H; Ren Y
    Diabetes Metab Syndr Obes; 2022; 15():2521-2534. PubMed ID: 35999869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.
    Jensterle M; Kravos NA; Pfeifer M; Kocjan T; Janez A
    Hormones (Athens); 2015; 14(1):81-90. PubMed ID: 25885106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight beneficial treatments for type 2 diabetes.
    Meneghini LF; Orozco-Beltran D; Khunti K; Caputo S; Damçi T; Liebl A; Ross SA
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3337-53. PubMed ID: 21900381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.